Zentalis Pharmaceuticals, Inc. announced the pricing of its initial public offering of 9,180,000 shares of common stock at a public offering price of $18.00 per share, for total gross proceeds of approximately $165.2 million, before deducting underwriting discounts and commissions and offering expenses payable by Zentalis.
April 2, 2020
· 2 min read